Replies to post #141068 on Biotech Values

[genisi]

Suvorexant profile looks suitable for chronic use and I assume its side effect data are better due to its shorter t½ than that of the now discontinued almorexant from GSK/Actelion.

[ariadndndough]

Biotech Jim. Is this data enough for the label to be best in class

[DewDiligence]

MRK—If all this pans out, suvorexant could be a monumental blockbuster. However, it sounds too good to be true; there have been many, many sleep drugs that ended up disappointing.